Artelo biosciences selected for oral presentation at the 32nd annual icrs symposium in galway, ireland

Solana beach, calif., june 24, 2022 (globe newswire) -- artelo biosciences, inc.  (nasdaq: artl) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that professor saoirse o'sullivan, artelo's vice president of translational sciences, has been selected for an oral presentation at the 32nd international cannabinoid research society (icrs) symposium, on sunday, june 26th. dr. sullivan will be presenting pre-clinical data related to art26.12, the company's lead fatty acid binding protein 5 (fabp5) inhibitor. the company plans to provide a summary of the research following the presentation. the icrs symposium is being held at the bailey allen hall at the national university of ireland, galway, from june 25-30, 2022.
ARTL Ratings Summary
ARTL Quant Ranking